» Articles » PMID: 35444630

Strategy of Developing Oral Vaccine Candidates Against Co-infection of Porcine Diarrhea Viruses Based on a Delivery System

Overview
Journal Front Microbiol
Specialty Microbiology
Date 2022 Apr 21
PMID 35444630
Authors
Affiliations
Soon will be listed here.
Abstract

The number of co-infections with multiple porcine diarrhea viruses has increased in recent years. Inducing mucosal immunity through oral immunization is an effective approach for controlling these pathogens. To generate a multi-pathogen vaccine against viral co-infection, we employed the vector platform, which was previously used to generate potent candidate vaccines against various diseases. Two strategies were used to test the protective efficiency of recombinant against multiple diarrhea viruses. First, we used a mixture of recombinant separately expressing antigens of transmissible gastroenteritis virus (TGEV), porcine epidemic diarrhea virus (PEDV), and porcine rotavirus (PoRV). Next, we used a recombinant expressing an antigen fusion protein of the above viruses. Twenty-four newborn piglets were divided into three groups and orally immunized with a mixture of recombinant , recombinant expressing the antigen fusion protein, or sterile phosphate-buffered saline daily for seven consecutive days after birth. After immunization, the piglets were randomly selected from each group for oral administration of PEDV, and these piglets were then cohabited with piglets without PEDV infection for 7 days. The protective effect against PEDV was evaluated based on clinical symptoms, viral shedding, and intestinal pathological damage. Piglets immunized with recombinant showed specific mucosal and humoral immune responses to the three viruses and were protected against severe diarrhea and intestinal pathology. Our results highlight the potential of an oral multi-pathogen vaccine based on to prevent transmission and limit the severity of viral co-infection.

Citing Articles

Feed Supplementation Combined with Oral Immunization in Sows as a Tool to Reduce Neonatal Diarrhea in Piglets.

Liu J, Yang D, Qu H, Liu D, Huang K Animals (Basel). 2024; 14(13).

PMID: 38998090 PMC: 11240787. DOI: 10.3390/ani14131978.


Screening optimal DC-targeting peptide to enhance the immune efficacy of recombinant expressing RHDV VP60.

Xia T, Lu X, Kong D, Guo T, Gao Y, Xin L Virulence. 2024; 15(1):2368080.

PMID: 38899573 PMC: 11195490. DOI: 10.1080/21505594.2024.2368080.


Epitope screening and vaccine molecule design of PRRSV GP3 and GP5 protein based on immunoinformatics.

Liu D, Chen Y J Cell Mol Med. 2024; 28(3):e18103.

PMID: 38217314 PMC: 10844699. DOI: 10.1111/jcmm.18103.


Development of a Genetically Engineered Bivalent Vaccine against Porcine Epidemic Diarrhea Virus and Porcine Rotavirus.

Li W, Lei M, Li Z, Li H, Liu Z, He Q Viruses. 2022; 14(8).

PMID: 36016368 PMC: 9413861. DOI: 10.3390/v14081746.


Epidemic and Evolutionary Characteristics of Swine Enteric Viruses in South-Central China from 2018 to 2021.

Li C, Lu H, Geng C, Yang K, Liu W, Liu Z Viruses. 2022; 14(7).

PMID: 35891398 PMC: 9323342. DOI: 10.3390/v14071420.

References
1.
Renukuntla J, Vadlapudi A, Patel A, Boddu S, Mitra A . Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm. 2013; 447(1-2):75-93. PMC: 3680128. DOI: 10.1016/j.ijpharm.2013.02.030. View

2.
Marasini N, Skwarczynski M, Toth I . Oral delivery of nanoparticle-based vaccines. Expert Rev Vaccines. 2014; 13(11):1361-76. DOI: 10.1586/14760584.2014.936852. View

3.
Holmgren J, Czerkinsky C . Mucosal immunity and vaccines. Nat Med. 2005; 11(4 Suppl):S45-53. DOI: 10.1038/nm1213. View

4.
Neutra M, Kozlowski P . Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006; 6(2):148-58. DOI: 10.1038/nri1777. View

5.
Zhao L, Guo Z, Liu J, Wang Z, Wang R, Li Y . Recombinant Lactobacillus casei expressing Clostridium perfringens toxoids α, β2, ε and β1 gives protection against Clostridium perfringens in rabbits. Vaccine. 2017; 35(32):4010-4021. DOI: 10.1016/j.vaccine.2017.05.076. View